By Sabela Ojea
Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema.
The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year.
The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial.
Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health.
The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 28, 2024 12:00 ET (16:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.